Biomedical Journal of Indonesia
Journal Homepage: https://bji-fk.ejournal.unsri.ac.id

Anti-Inflammatory and Anti-Hyperuricemic Effects of Chrysin in a Rat Model of High Fructose Corn Syrup Induced Hyperuricemia

Hanifah Tahany[1], Nita Parisa[2*], M Daffa Nugraha[1], Debby Handayati Harahap[2], Theodorus[2]

[1]Postgraduate of Medical Doctor, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
[2]Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

ARTICLE INFO

Keywords:
Chrysin
Uric acid
Inflammasome
Hyperuricemia

Corresponding author:
Nita Parisa

E-mail address:
nitaparisa@unsri.ac.id

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.32539/BJI.v11i1.200

ABSTRACT

An increase in the blood level of uric acid, or hyperuricemia, is a disorder that can cause damage to the kidneys and gout among other health problems. Worldwide, the incidence of hyperuricemia has been rising, in part because of dietary factors such the use of HFCS, a prevalent sweetener found in processed foods. Thus, research into natural substances with anti-inflammatory and anti-hyperuricemia attributes, such as chrysin, is critical to the fields of therapeutic and preventive medicine. This study investigates the anti-inflammatory and anti-hyperuricemic effects of chrysin in a rat model of hyperuricemia induced by high-fructose corn syrup. The research reveals that chrysin exerts its therapeutic effects through antioxidant activity and the inhibition of inflammatory signaling pathways, resulting in a decrease in oxidative stress and the expression of the pro-inflammatory cytokine IL-1β. Treatment with chrysin leads to a significant increase in tissue weight, tissue index, and kidney histology, indicating its potential in mitigating kidney damage associated with hyperuricemia. The study demonstrates a dose-dependent reduction in IL-1β levels and inflammation activation with chrysin treatment, surpassing the anti-inflammatory effects of the comparison group. Furthermore, chrysin treatment reduces malondialdehyde concentration and mitigates the activation of inflammasome-related protein induced by high-fructose corn syrup. These findings highlight the promising therapeutic potential of chrysin in managing hyperuricemia and related metabolic disorders.

1. Introduction

Hyperuricemia, a prevalent metabolic disorder linked to illnesses including gout, renal disease, cardiovascular disease, and metabolic syndrome, is marked by excessive blood levels of uric acid.[1] Consuming meals high in purines and high fructose corn syrup contributes to the increasing prevalence of hyperuricemia, which calls for effective treatments to manage this illness. In addition to being a risk factor for gout, hyperuricemia is also associated with major health problems such as metabolic disorders, hypertension, and chronic renal disease.[2,3] It is vital to investigate novel approaches for controlling uric acid levels and mitigating inflammation in order to avert and handle health issues linked to hyperuricemia. Study findings have practical implications for individuals in terms of food choices and potential therapeutic approaches.[4]

By highlighting the positive impact of chrysin in lowering uric acid levels and inflammation, individuals may consider integrating natural compounds like chrysin into their diet or treatment plans to enhance overall health and quality of life.[5] Recognizing chrysin as a promising adjunct therapy for hyperuricemia and inflammation paves the way for the development of targeted therapies to address the underlying mechanisms of hyperuricemia and related inflammatory responses.[6] Chrysin's ability to regulate urate transporters and inhibit the NLRP3 inflammasome signaling pathway opens doors for targeted therapy development to address the underlying mechanisms of hyperuricemia and associated inflammatory responses.[6,7]

Fructose consumption has significantly increased over recent decades due to shifts in dietary patterns toward high-calorie foods and drinks, especially sugar-sweetened beverages and processed foods containing high-fructose corn syrup (HFCS) or sucrose. Reports from the International Sugar Organization indicate a rise in global average daily sugar intake from 56 g to 65 g between 1986 and 2007. In the Dutch National Food Consumption Survey from 2007–2010, the median daily fructose intake for individuals aged 7–69 was 46 g, slightly

lower than intake levels in the United States. This increase is largely driven by higher consumption of sugar-sweetened drinks, such as energy, fruit, and soft drinks, which are now leading sources of added sugars in modern diets.[8]

Numerous studies on hyperuricemia's epidemiology worldwide reflect its growing public health concern. In the United States, hyperuricemia affected up to 14.6% of adults, or an estimated 32.5 million people, in 2015–2016. Although the age-adjusted prevalence slightly declined from 32.5 million in 2007–08 to 32.1 million in 2015–16, the absolute number of affected individuals remains constant. Prevalence is notably higher in older adults, reaching 27.8% among those over 80 years. In China, hyperuricemia rates vary by region; as of 2018, an estimated 271 million Chinese adults may be affected based on data from 2014–2018, highlighting the scale of this issue in a large, developing country.[8]

Given the global burden of hyperuricemia and related comorbidities, research on natural compounds like chrysin with anti-inflammatory and anti-hyperuricemia properties is crucial for public health efforts.[9] Understanding the mechanistic actions of chrysin can guide the formulation of prevention and therapeutic interventions aimed at improving the management of hyperuricemia and its associated disorders.[10]

2. Anti-Inflammatory and Anti-Hyperuricemic Effects of Chrysin

This article provided an experimental model-based research rather than a systematic review, and it does not specify a literature review methodology involving article selection or inclusion/exclusion criteria for analyzing existing studies. Instead, it focuses on an experimental approach using a rat model to investigate the anti-hyperuricemic and anti-inflammatory effects of chrysin. The study's approach includes a controlled intervention with chrysin in high-fructose corn syrup (HFCS)-induced hyperuricemic rats, aiming to observe physiological and biochemical changes in response to the treatments specific dosages and controlled conditions to monitor urate transporter expression, oxidative stress markers, and NLRP3 inflammasome signaling.[9,10] This investigation fits within the realm of experimental studies, where animal models are used to simulate disease conditions and treatment effects rather than reviewing pre-existing literature broadly.

The article conducts an in-depth investigation into the potential therapeutic effects of chrysin in reducing hyperuricemia induced by high-fructose corn syrup (HFCS) in an animal model. The study design involved rats divided into different experimental groups, including a control group, a group with HFCS-induced hyperuricemia, a group receiving chrysin intervention at varying doses (50, 100, and 150 mg/kg body weight)[9], and a group treated with allopurinol (a standard drug for hyperuricemia).[11] Hyperuricemia was induced in rats by administering a 10% HFCS solution over a 12-week period, with Chrysin or allopurinol treatment initiated from Week 8 to Week 12.[11] The intervention was delivered orally once a day, while the control group received a CMC-Na solution.[11,12]

Urine samples were collected from rats housed in metabolic cages overnight to assess urine characteristics. Blood samples were collected and centrifuged to obtain serum for biochemical examinations including uric acid, blood urea nitrogen, creatinine, glucose, cholesterol levels, and others.[13] Serum and urine samples were analyzed using an automatic chemical analyzer to measure various biochemical parameters related to kidney and liver function, lipid profile, and uric acid metabolism.[11]

This study then examined the expression of urate transporters, including GLUT9, URAT1, OAT1, and ABCG2, to explore the influence of Chrysin on uric acid transportation and excretion.[11] Assessment of inflammatory markers such as interleukin 1 beta (IL-1β) and malondialdehyde (MDA) was measured in the kidneys and serum to evaluate the anti-inflammatory properties of chrysin and its impact on the NLRP3 inflammasome signaling pathway.[11]

Histological assessment of the kidneys was conducted to evaluate structural changes or damage in response to hyperuricemia and chrysin intervention. Data analysis included statistical methodology to compare the effects of chrysin intervention on hyperuricemia, inflammation, and urate transporter expression in a rat model.[11,14]

This research yielded important findings in the form of reduced uric acid levels. Treatment with chrysin resulted in a significant decrease in serum uric acid levels compared to the HFCS-exposed group, indicating the potential of chrysin as an anti-hyperuricemic agent. Chrysin also increased the excretion of uric acid in urine and enhanced the uric acid excretion fraction, demonstrating its ability to facilitate the excretion of uric acid from the body.[14]

Furthermore, as a modulator of urate transporters, chrysin administration affected the expression of urate transporter proteins such as OAT1, ABCG2, URAT1, and GLUT9 in the kidneys, highlighting its role in regulating the mechanisms of uric acid transportation and excretion.[12] Modulation of urate transporters by chrysin likely contributed to the observed decrease in serum uric acid levels and increased uric acid excretion in this study.[14]

Chrysin demonstrates significant anti-inflammatory effects by reducing the expression of pro-inflammatory cytokine IL-1β both in the serum and kidney tissues of hyperuricemic rats.[11] This study suggests that the anti-inflammatory properties of chrysin are superior to allopurinol, the standard drug for hyperuricemia, confirming the potential of chrysin as a natural anti-inflammatory agent.[13,15] Both chrysin and allopurinol effectively reduce

inflammasome activation caused by oxidative stress, as evidenced by decreased concentrations of MDA and reduced levels of inflammasome-related proteins (ASC, pro-Caspase 1, NLRP3) in the kidney. These results indicate that chrysin's ability to reduce oxidative stress and inhibit inflammasome activation contributes to its overall anti-inflammatory effects and therapeutic potential in the context of hyperuricemia.[16]

The findings of this research are in line with other scientific discoveries. Previous studies have also demonstrated the anti-hyperuricemic properties of chrysin through mechanisms such as inhibiting xanthine oxidase activity, facilitating uric acid excretion, and modulating urate transporter expression. Consistent with the current research, chrysin's capacity to reduce serum uric acid levels and increase uric acid excretion align with the results of previous investigations, strengthening its potential as a therapeutic intervention for hyperuricemia.[13,14]

Research has highlighted chrysin's anti-inflammatory attributes, including its ability to suppress pro-inflammatory cytokines like IL-1β and regulate inflammasome activation in various pathological contexts. The current research findings regarding chrysin's superior anti-inflammatory effects compared to allopurinol are consistent with existing literature, affirming the proposition that chrysin can serve as a potent natural anti-inflammatory agent.[13,15]

Studies have shown that chrysin can affect the expression and function of urate transporters involved in uric acid metabolism, similar to modulation observed in current research with OAT1, ABCG2, URAT1, and GLUT9.[12] Consistency in urate transporter modulation by chrysin in various investigations suggests potential mechanisms through which chrysin exerts its anti-hyperuricemic effect and supports chrysin's role in regulating uric acid transportation.[15]

This study used high-fructose corn syrup (HFCS) to induce hyperuricemia in rats because HFCS has been shown to be a potent inducer of elevated uric acid levels due to the specific way fructose is metabolized in the body. Unlike glucose, fructose is primarily processed in the liver, where it can lead to rapid ATP depletion and the production of uric acid as a byproduct.[11,15]

Fructose intake stimulates the breakdown of ATP to AMP, which is quickly converted into inosine monophosphate and eventually into uric acid through the action of the enzyme xanthine oxidase (XO). The rapid consumption of ATP and subsequent increase in uric acid levels are key contributors to hyperuricemia. In other words, HFCS elevates uric acid because its high fructose content results in a direct pathway to increased uric acid production.[15]

Fructose metabolism not only increases uric acid production but also hampers its excretion by the kidneys. When fructose is metabolized, it competes with uric acid for excretion. This competition occurs because both fructose and uric acid are filtered and excreted through similar renal transport mechanisms. Consequently, high-fructose diets lead to an accumulation of uric acid in the bloodstream.[15]

High uric acid levels are associated with oxidative stress and inflammation, which can activate pathways like the NLRP3 inflammasome, a key pro-inflammatory pathway. HFCS-induced hyperuricemia, therefore, not only models elevated uric acid but also simulates the inflammatory and oxidative conditions associated with metabolic disorders like kidney disease and cardiovascular disease. This makes it a relevant model for studying both the hyperuricemic and inflammatory effects that could be mitigated by compounds with antioxidant and anti-inflammatory properties, such as chrysin.[15]

HFCS is prevalent in modern diets, especially in sugar-sweetened beverages and processed foods. Its widespread use has been correlated with increased rates of metabolic disorders, including hyperuricemia and associated conditions like gout, hypertension, and obesity. Using HFCS in this model allows the study to closely mimic real-world dietary conditions and provides insights into how typical high-sugar diets contribute to uric acid-related diseases. By using HFCS, the study also gains relevance to public health and dietary patterns, making it applicable for evaluating potential therapeutic agents.[15]

HFCS was chosen because it effectively induces hyperuricemia by both increasing uric acid production and reducing its excretion, and because it mimics common dietary habits associated with metabolic and inflammatory diseases. This provides a robust model to evaluate the effects of chrysin on hyperuricemia and inflammation.[11,13,14,15]

Further research efforts have highlighted chrysin's ability to alleviate oxidative stress, reduce inflammasome activation, and suppress inflammatory responses in various pathological conditions. The current study findings on chrysin's influence on inflammasome activation caused by oxidative stress align with existing research, indicating a consistent pattern of chrysin's anti-inflammatory and antioxidant properties.[13,15]

The results of this research may be unique to this experimental design as it utilizes a high-fructose corn syrup-induced hyperuricemia rat model. Diverse studies may yield different results due to variations in treatment protocols, experimental conditions, and animal models.[15,17]

Findings suggest that chrysin inhibits inflammatory signaling pathways and possesses antioxidant properties against hyperuricemia. Although the antioxidant quality of chrysin has been the subject of other studies, this research might be the first to investigate the effects of high-fructose corn syrup specifically on hyperuricemia.[16,17]

3. Strengths and Limitations

Scientific article discussing the anti-inflammatory and anti-hyperuricemic effects of chrysin in a high-fructose corn syrup-induced hyperuricemia rat model describes several strengths that enhance its scientific significance and potential implications:[11]

a. Novelty of Research

This study explores the impact of chrysin on hyperuricemia induced by high-fructose corn syrup, addressing an area that is relevant but not yet explored in the realm of metabolic disorders and inflammation.[11,18] The novelty in this research enriches its contribution to the existing body of literature.

b. Comprehensive Experimental Design

The study adopts a well-structured experimental design, involving multiple treatment groups with varying doses of chrysin, control groups, biochemical analysis, histological evaluation, and molecular assessment. This comprehensive approach allows for a thorough evaluation of the effects of chrysin.

c. Mechanistic Insights

By investigating the underlying mechanisms of chrysin's actions, such as its influence on urate transporters, oxidative stress, inflammasome activation, and pro-inflammatory cytokines, this research offers valuable mechanistic insights into the anti-hyperuricemic and anti-inflammatory properties of chrysin.

d. Clear Presentation of Results

This study presents its findings clearly and well-structured, including tables, figures, and supplementary materials that enhance the understanding of the experimental results. Transparent reporting of results aids in the interpretation and dissemination of research.

e. Author Contributions and Collaboration

This article acknowledges the contributions of multiple authors with diverse expertise, demonstrating collaborative efforts in conceptualization, experimentation, data analysis, methodology, and writing. This multidisciplinary approach strengthens the rigor and credibility of the study.

f. Relevance to Human Health

The focus of the study on metabolic diseases associated with hyperuricemia and the potential therapeutic benefits of chrysin has direct relevance to human health and clinical applications. These findings could pave the way for further exploration of chrysin as a natural compound for managing hyperuricemia and its related conditions.

g. Implications for Future Research

The results and conclusions of this study form the basis for future research directions, including clinical investigations, mechanistic explorations, dose optimization, and exploration of the therapeutic potential of chrysin in human hyperuricemia. The implications of this study extend beyond its current findings, offering pathways for future research efforts.

This research provides valuable insights; however, several limitations are considered, namely:

a. Animal Model Specificity

This study used a hyperuricemia rat model induced by high-fructose corn syrup. Although animal models are crucial for preclinical research, translating results to human conditions may be limited by species variations in metabolism and disease pathophysiology.

b. Dose-Response Relationship

Examining various doses of chrysin (50, 100, and 150 mg/kg)[11] for hyperuricemia is commendable; however, a more detailed dose-response analysis involving additional concentrations could provide a more precise understanding of optimal therapeutic doses and dose-dependent effects.

c. Mechanistic Understanding

While this study discusses the mechanisms by which chrysin affects uric acid metabolism, inflammation, and inflammasome signaling, further explanations on the specific molecular pathways involved and interactions among these processes could advance the understanding of chrysin's mechanism of action.

d. Treatment Duration

The treatment duration of this study may be relatively short to capture the long-term effects of chrysin on hyperuricemia and related metabolic disorders.[7] Extended longitudinal studies could offer insights into sustained efficacy and safety profile of chrysin.

e. Clinical Translation

Despite showing promising results in a preclinical context, translating the effects of chrysin from animal models to clinical applications for human hyperuricemia requires further validation through well-designed clinical trials evaluating safety, effectiveness, and potential adverse effects.

f. Sample Size and Statistical Analysis

This study lacks explicit details on sample size calculations, randomization procedures, and statistical analysis methods. Transparent reporting of these elements is crucial to ensure the robustness and reliability of the study findings.

g. Publication Bias

Publishing a study in a single journal without replication or validation by an independent research group introduces the potential for publication bias. Conducting replication studies and disseminating findings through various publication channels can enhance the credibility and generalizability of the results.

Overall, the strength of this article lies in its innovative approach, comprehensive design, mechanistic insights, clear presentation of results, collaborative authors, relevance to human health, and potential to guide future research in the fields of

hyperuricemia and inflammation. These strengths collectively contribute to the scientific significance and research impact on the effects of chrysin on hyperuricemia.[17,19]

Addressing these limitations through rigorous experimental design, comprehensive mechanistic investigations, long-term studies, translational research, and transparent reporting practices can strengthen the scientific validity and clinical relevance of studies on the effects of chrysin on hyperuricemia.[19,20,21]

Although these research findings provide valuable insights into the effects of chrysin on hyperuricemia and inflammation in specific experimental contexts, further comparative analysis with existing literature and studies on the effects of chrysin on different hyperuricemia models is needed to determine the uniqueness or consistency of the findings. Conducting meta-analyses or systematic reviews that integrate findings from various studies can help elucidate the overall impact of chrysin on hyperuricemia and inflammation across different experimental settings.

4. Conclusion

Chrysin has the potential for anti-inflammatory effects on hyperuricemia, proven by its ability to reduce IL-1β levels. By inhibiting inflammatory signals and acting as an antioxidant, chrysin lowers hyperuricemia. It reduces inflammation activation and oxidative stress caused by high fructose corn syrup in hyperuricemic rats, showing positive effects on kidney health. This study suggests further investigation into the use of chrysin for treating hyperuricemia in humans. Focusing on specific pathways, chrysin demonstrates promising results in managing inflammation and hyperuricemia. The potential of chrysin in addressing hyperuricemia and inflammation indicates its promising role in future clinical applications and research.

5. Acknowledgements

None

6. References

1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016; 388: 2039–2052.
2. Juraschek SP, Kovell LC, Miller III ER, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Semin Arthritis Rheum. 2013; 42: 551–561.
3. Mandal AK, Mount DB. The Molecular Physiology of Uric Acid Homeostasis. Annu Rev Physiol. 2015; 77: 323–345.
4. Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: A potential target for future therapeutics. Hum Reprod Update. 2017; 24: 59–85.
5. Tan J, Wan L, Chen X, Li X, Hao X, Li J, Ding H. Conjugated Linoleic Acid Ameliorates High Fructose-Induced Hyperuricemia and Renal Inflflammation in Rats via NLRP3 Inflflammasome and TLR4 Signaling Pathway. Mol Nutr Food Res. 2019; 63: e1801402.
6. Ziga N, Becic F. Allopurinol Effect on Values of Lipid Profile Fractions in Hyperuricemic Patients Diagnosed with Metabolic Syndrome. Mater Socio Med. 2013; 25: 167–169.
7. Mani R, Natesan V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry 2018; 145: 187–196.
8. Zhang C, Li L, Zhang Y, Zeng C. Recent advances in fructose intake and risk of hyperuricemia. Biomedicine & Pharmacotherapy. 2020 Nov;131: 110795.
9. Sultana S, Verma K, Khan R. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress. J. Pharm Pharmacol. 2012; 64: 872–881.
10. Ali BH, Al Za'abi M, Adham SA, Yasin J, Nemmar A, Schupp N. Therapeutic Effect of Chrysin on Adenine-Induced Chronic Kidney Disease in Rats. Cell Physiol Biochem. 2016; 38: 248–257.
11. Chang YH, Chiang YF, Chen HY, Huang YJ, Wang KL, Hong YH, Ali M, Shieh TM, Hsia SM. Anti-inflammatory and anti-hyperuricemic effects of chrysin on a high fructose corn syrup-induced hyperuricemia rat model via the amelioration of urate transporters and inhibition of NLRP3 inflammasome signaling pathway. Antioxidants. 2021; 10(4): 564.
12. Meng Z, Yan Y, Tang Z, Guo C, Li N, Huang W, Ding G, Wang Z, Xiao W, Yang Z. Anti-Hyperuricemic and Nephroprotective Effects of Rhein in Hyperuricemic Mice. Planta Med. 2015; 81: 279–285.
13. Kretowicz M, Johnson RJ, Ishimoto T, Nakagawa T, Manitius J. The Impact of Fructose on Renal Function and Blood Pressure. Int J Nephrol. 2011; 2011(1): 315879.
14. Jung SW, Kim SM, Kim YG, Lee SH, Moon JY. Uric acid and inflammation in kidney disease. Am J Physiol-Renal Physiol. 2020; 318(6): F1327-40.
15. Chen G, Tan ML, Li KK, Leung PC, Ko CH. Green tea polyphenols decrease uric acid level through xanthine oxidase and renal urate transporters in hyperuricemic mice. J. Ethnopharmacol. 2015; 175: 14–20.
16. Lu C, Tang S, Han J, Fan S, Huang Y, Zhang Z, Zhou J, Ming T, Li Y, Su X. Apostichopus japonicus Oligopeptide Induced Heterogeneity in the Gastrointestinal Tract Microbiota and Alleviated Hyperuricemia in a Microbiota-Dependent Manner. Mol Nutr Food Res. 2021; 65(14): e2100147
17. Arakawa H, Amezawa N, Kawakatsu Y, Tamai I. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9. Biol

Pharm Bull. 2020; 43: 1792–1798.
18. Aslan C, Aslankoc R, Ozmen O, Suluk BN, Kavrik O, Gumral N. Protective effect of vitamin D on learning and memory impairment in rats induced by high fructose corn syrup. Behavioural Brain Research. 2023.
19. Su HY, Yang C, Liang D, Liu HF. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. BioMed Res Int. 2020; 2020: 5817348.
20. Xiao J, Zhang XL, Fu C, Han R, Chen W, Lu Y, Ye Z. Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med. 2015; 35: 1347–1354.
21. Liao T, Ding L, Wu P, Zhang L, Li X, Xu B, Zhang H, Ma Z, Xiao Y, Wang P. Chrysin Attenuates the NLRP3 Inflammasome Cascade to Reduce Synovitis and Pain in KOA Rats. Drug Des Devel Ther. 2020; 14: 3015–3027.